{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:25:36Z","timestamp":1786994736230,"version":"build-2736575974"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.neuint.2026.106149","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:51:32Z","timestamp":1774630292000},"page":"106149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRISPR-Cas systems"],"prefix":"10.1016","volume":"196","author":[{"given":"Ravi Pratap","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasenjit","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3390\/genes16080850","article-title":"CRISPR in neurodegenerative diseases treatment: an alternative approach to current therapies","volume":"16","author":"Akbar","year":"2025","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.neuint.2026.106149_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12033-022-00501-4","article-title":"An insight into modern targeted genome-editing technologies with a special focus on CRISPR\/Cas9 and its applications","volume":"65","author":"Akram","year":"2023","journal-title":"Mol. Biotechnol."},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib3","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.1111\/ejn.16541","article-title":"Extracellular vesicle and CRISPR gene therapy: current applications in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease","volume":"60","author":"Akyuz","year":"2024","journal-title":"Eur. J. Neurosci."},{"issue":"9","key":"10.1016\/j.neuint.2026.106149_bib4","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3390\/cells10092342","article-title":"Applications of CRISPR-Cas9 technology to genome editing in glioblastoma multiforme","volume":"10","author":"Al-Sammarraie","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib5","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","article-title":"CRISPR\/Cas9 mediated therapeutic approach in Huntington's disease","volume":"60","author":"Alkanli","year":"2023","journal-title":"Mol. Neurobiol."},{"issue":"17","key":"10.1016\/j.neuint.2026.106149_bib7","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.3390\/ijms22179241","article-title":"Understanding the potential of genome editing in Parkinson's Disease","volume":"22","author":"Arango","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2026.106149_bib8","series-title":"The CRISPR\/Cas Tool Kit for Genome Editing","first-page":"219","article-title":"RNA editing with CRISPR\/Cas13","author":"Ashraf","year":"2022"},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/brainsci11030373","article-title":"Modelling Parkinson's disease: iPSCs towards better understanding of human pathology","volume":"11","author":"Avazzadeh","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuint.2026.106149_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107742","article-title":"alpha-synuclein, autophagy-lysosomal pathway, and Lewy bodies: mutations, propagation, aggregation, and the formation of inclusions","author":"Bayati","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 2","key":"10.1016\/j.neuint.2026.106149_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood\u2013brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.neuint.2026.106149_bib12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s11481-019-09878-7","article-title":"A broad application of CRISPR Cas9 in infectious diseases of central nervous system","volume":"14","author":"Bellizzi","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib13","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbadis.2016.11.010","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders\u2014A step towards mitochondria based therapeutic strategies","volume":"1863","author":"Bhatti","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.neuint.2026.106149_bib14","series-title":"Intelligent Technologies and Parkinson's Disease: Prediction and Diagnosis","first-page":"199","article-title":"Genetic determinants of Parkinson's Disease: SNCA and LRRK2 in focus","author":"Bhuvaneswari","year":"2024"},{"key":"10.1016\/j.neuint.2026.106149_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.conb.2024.102858","article-title":"Functional neurogenomics in autism spectrum disorders: a decade of progress","volume":"86","author":"Bicks","year":"2024","journal-title":"Curr. Opin. Neurobiol."},{"issue":"10","key":"10.1016\/j.neuint.2026.106149_bib16","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.drudis.2020.07.024","article-title":"High-throughput screening: today's biochemical and cell-based approaches","volume":"25","author":"Blay","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuint.2026.106149_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coviro.2016.08.004","article-title":"Adeno-associated virus and lentivirus vectors: a refined toolkit for the central nervous system","volume":"21","author":"Blessing","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.neuint.2026.106149_bib18","article-title":"Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model of Parkinson's disease","volume":"13","author":"Boeck","year":"2024","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/scipharm87010006","article-title":"Overcoming the blood\u2013brain barrier. challenges and tricks for CNS drug delivery","volume":"87","author":"Bors","year":"2019","journal-title":"Sci. Pharm."},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.tins.2022.05.001","article-title":"Induced pluripotent stem cells: a tool for modeling Parkinson's disease","volume":"45","author":"Bose","year":"2022","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/biomedicines12030549","article-title":"Some novel therapies in parkinson's disease: a promising path forward or not yet? A systematic review of the literature","volume":"12","author":"Bougea","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/jmg.2008.063917","article-title":"Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control","volume":"46","author":"Brooks","year":"2009","journal-title":"J. Med. Genet."},{"issue":"10","key":"10.1016\/j.neuint.2026.106149_bib23","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/cells11101596","article-title":"Long-term evaluation of intranigral transplantation of human iPSC-derived dopamine neurons in a Parkinson's disease mouse model","volume":"11","author":"Brot","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib24","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0733-8619(18)31084-3","article-title":"Pharmacology of Parkinson's disease","volume":"2","author":"Burton","year":"1984","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.neuint.2026.106149_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.pbr.2019.11.002","article-title":"What we can learn from iPSC-derived cellular models of Parkinson's disease","volume":"252","author":"Caiazza","year":"2020","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuint.2026.106149_bib27","author":"Caplan"},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/biom14080949","article-title":"Novel therapeutic Horizons: SNCA targeting in parkinson's disease","volume":"14","author":"Caramiello","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuint.2026.106149_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fgeed.2020.00007","article-title":"The iNs and outs of direct reprogramming to induced neurons","volume":"2","author":"Carter","year":"2020","journal-title":"Front. Genome Edit."},{"issue":"10","key":"10.1016\/j.neuint.2026.106149_bib30","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/biology12101298","article-title":"An integrated multi-omics and artificial intelligence framework for advance plant phenotyping in horticulture","volume":"12","author":"Cembrowska-Lech","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.neuint.2026.106149_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.02.037","article-title":"Biophysical mechanisms underlying the membrane trafficking of synaptic adhesion molecules","volume":"169","author":"Chamma","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/0115665232275754231204072320","article-title":"CRISPR-Based therapies: revolutionizing drug development and precision medicine","volume":"24","author":"Chanchal","year":"2024","journal-title":"Curr. Gene Ther."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","article-title":"Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy","volume":"23","author":"Chehelgerdi","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","article-title":"Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy","volume":"23","author":"Chehelgerdi","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.molcel.2017.09.014","article-title":"Randomized CRISPR-Cas transcriptional perturbation screening reveals protective genes against alpha-synuclein toxicity","volume":"68","author":"Chen","year":"2017","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/ejn.14286","article-title":"Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene","volume":"49","author":"Chen","year":"2019","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.biocel.2004.09.009","article-title":"Dopaminergic neurons","volume":"37","author":"Chinta","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuint.2026.106149_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fnmol.2020.589109","article-title":"Neurogenetic and neuroepigenetic mechanisms in cognitive health and disease","volume":"13","author":"Coda","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"15","key":"10.1016\/j.neuint.2026.106149_bib39","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1101\/gad.304055.117","article-title":"RNA-binding proteins in neurodegeneration: mechanisms in aggregate","volume":"31","author":"Conlon","year":"2017","journal-title":"Genes Dev."},{"issue":"12","key":"10.1016\/j.neuint.2026.106149_bib40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrn2935","article-title":"The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease","volume":"11","author":"Cookson","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib41","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1152\/physrev.00022.2010","article-title":"What genetics tells us about the causes and mechanisms of Parkinson's disease","volume":"91","author":"Corti","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuint.2026.106149_bib42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fnmol.2019.00110","article-title":"Editing the central nervous system through CRISPR\/Cas9 systems","volume":"12","author":"Cota-Coronado","year":"2019","journal-title":"Front. Mol. Neurosci."},{"issue":"9","key":"10.1016\/j.neuint.2026.106149_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010430","article-title":"A genome-wide CRISPR screen identifies DPM1 as a modifier of DPAGT1 deficiency and ER stress","volume":"18","author":"Dalton","year":"2022","journal-title":"PLoS Genet."},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00425-022-03894-3","article-title":"Recent advancements in CRISPR\/Cas technology for accelerated crop improvement","volume":"255","author":"Das","year":"2022","journal-title":"Planta"},{"key":"10.1016\/j.neuint.2026.106149_bib46","first-page":"1","article-title":"Insights of CRISPR-Cas systems in stem cells: progress in regenerative medicine","author":"Dilip Kumar","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1152\/physrev.1961.41.1.130","article-title":"The blood-brain barrier","volume":"41","author":"Dobbing","year":"1961","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.conb.2007.04.010","article-title":"Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease","volume":"17","author":"Dodson","year":"2007","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuint.2026.106149_bib49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington's disease mouse model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.neuint.2026.106149_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1138596","article-title":"Immunogenicity of CRISPR therapeutics\u2014Critical considerations for clinical translation","volume":"11","author":"Ewaisha","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"2","key":"10.1016\/j.neuint.2026.106149_bib51","article-title":"Lipid nanoparticles: the game-changer in CRISPR-Cas9 genome editing","volume":"10","author":"Farsani","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.neuint.2026.106149_bib52","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.pnpbp.2017.05.019","article-title":"CRISPR-engineered genome editing for the next generation neurological disease modeling","volume":"81","author":"Feng","year":"2018","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuint.2026.106149_bib53","first-page":"39","article-title":"CRISPR\/Cas9 and mitochondrial gene replacement therapy: promising techniques and ethical considerations","volume":"5","author":"Fogleman","year":"2016","journal-title":"Am J. Stem Cells"},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib54","first-page":"1359","article-title":"Legal and ethical implications of CRISPR applications in psychiatry","volume":"97","author":"Foulkes","year":"2019","journal-title":"N. C. Law Rev."},{"key":"10.1016\/j.neuint.2026.106149_bib55","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3389\/fbioe.2020.00692","article-title":"Exploiting CRISPR Cas9 in three-dimensional stem cell cultures to model disease","volume":"8","author":"Gopal","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib56","doi-asserted-by":"crossref","DOI":"10.1042\/AN20090007","article-title":"Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions","volume":"1","author":"Greggio","year":"2009","journal-title":"ASN Neuro"},{"key":"10.1016\/j.neuint.2026.106149_bib57","article-title":"Base editors: expanding the types of DNA damage products harnessed for genome editing","volume":"1","author":"Gu","year":"2021","journal-title":"Gene Genome Edit."},{"key":"10.1016\/j.neuint.2026.106149_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.neuint.2026.106149_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mehy.2017.11.009","article-title":"Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction","volume":"110","author":"Hagan","year":"2018","journal-title":"Med. Hypotheses"},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib60","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.stem.2015.01.018","article-title":"Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease","volume":"16","author":"Hallett","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/crispr.2019.0042","article-title":"Societal and ethical impacts of germline genome editing: how can we secure human rights?","volume":"2","author":"Halpern","year":"2019","journal-title":"CRISPR J."},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib62","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jama.2015.19150","article-title":"Ethical and societal questions loom large as gene editing moves closer to the clinic","volume":"315","author":"Hampton","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib63","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-020-01893-z","article-title":"Mitigating off-target effects in CRISPR\/Cas9-mediated in vivo gene editing","volume":"98","author":"Han","year":"2020","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","article-title":"Mitochondrial dysfunction in Parkinson's disease\u2013a key disease hallmark with therapeutic potential","volume":"18","author":"Henrich","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","article-title":"A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering","volume":"65","author":"Hillary","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.neuint.2026.106149_bib66","series-title":"Clinical Ethics at the Crossroads of Genetic and Reproductive Technologies","first-page":"205","article-title":"Stem cell therapies for neurodegenerative disorders: an ethical analysis","author":"Hostiuc","year":"2018"},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2019.107447","article-title":"CRISPR technologies for stem cell engineering and regenerative medicine","volume":"37","author":"Hsu","year":"2019","journal-title":"Biotechnol. Adv."},{"issue":"6923","key":"10.1016\/j.neuint.2026.106149_bib68","first-page":"281","article-title":"Parkinson's disease and its management","volume":"308","author":"Hughes","year":"1994","journal-title":"BMJ Br. Med. J. (Clin. Res. Ed.)"},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2516697","article-title":"Unlocking the potential: advancements and applications of gene therapy in severe disorders","volume":"57","author":"Ingle","year":"2025","journal-title":"Ann. Med."},{"issue":"10","key":"10.1016\/j.neuint.2026.106149_bib70","doi-asserted-by":"crossref","first-page":"24751","DOI":"10.3390\/ijms161024751","article-title":"Minimizing off-target mutagenesis risks caused by programmable nucleases","volume":"16","author":"Ishida","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.neuint.2026.106149_bib71","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00439-016-1691-5","article-title":"Gene correction in patient-specific iPSCs for therapy development and disease modeling","volume":"135","author":"Jang","year":"2016","journal-title":"Hum. Genet."},{"issue":"Suppl. l_1","key":"10.1016\/j.neuint.2026.106149_bib72","first-page":"S1","article-title":"Pharmacology of dopamine agonists in the treatment of Parkinson's disease","volume":"58","author":"Jenner","year":"2002","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib73","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.10.8.4","article-title":"The present and future of mitochondrial-based therapeutics for eye disease","volume":"10","author":"Ji","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib75","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.synbio.2020.08.003","article-title":"CRISPR base editing and prime editing: DSB and template-free editing systems for bacteria and plants","volume":"5","author":"Jiang","year":"2020","journal-title":"Synthetic Syst. Biotechnol."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib76","article-title":"Precision gene editing: the power of CRISPR-Cas in modern genetics. Molecular therapy","volume":"36","author":"Joo","year":"2025","journal-title":"Nucleic Acids"},{"issue":"7","key":"10.1016\/j.neuint.2026.106149_bib77","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.4103\/1673-5374.360289","article-title":"Mitochondria in Huntington's disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies","volume":"18","author":"Jurcau","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"9","key":"10.1016\/j.neuint.2026.106149_bib78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41582-020-0373-z","article-title":"CRISPR-based functional genomics for neurological disease","volume":"16","author":"Kampmann","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.neuint.2026.106149_bib79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0962-8924(98)01383-X","article-title":"Molecular mechanisms of DNA double-strand break repair","volume":"8","author":"Kanaar","year":"1998","journal-title":"Trends Cell Biol."},{"issue":"17","key":"10.1016\/j.neuint.2026.106149_bib80","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2026.106149_bib81","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00018-004-4174-0","article-title":"DNA damage repair and transcription: double-strand breaks: signaling pathways and repair mechanisms","volume":"61","author":"Karagiannis","year":"2004","journal-title":"Cell. Mol. Life Sci. CMLS"},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib82","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.25499","article-title":"The many faces of alpha\u2010synuclein mutations","volume":"28","author":"Kasten","year":"2013","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib83","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.neuint.2026.106149_bib84","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/mds.25132","article-title":"Systematic review and UK\u2010based study of PARK2 (parkin), PINK1, PARK7 (DJ\u20101) and LRRK2 in early\u2010onset Parkinson's disease","volume":"27","author":"Kilarski","year":"2012","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib86","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.pa.33.040193.002343","article-title":"The pharmacology of Parkinson's disease therapy: an update","volume":"33","author":"Kopin","year":"1993","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuint.2026.106149_bib87","article-title":"Advances in delivery mechanisms of CRISPR gene-editing reagents in plants","volume":"4","author":"Laforest","year":"2022","journal-title":"Front. Genome Edit."},{"key":"10.1016\/j.neuint.2026.106149_bib88","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ymeth.2021.02.018","article-title":"CRISPR-Cas12-based nucleic acids detection systems","volume":"203","author":"Leung","year":"2022","journal-title":"Methods"},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib89","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/1521654031000153030","article-title":"Molecular mechanisms of neurodegeneration in Parkinson's disease: clues from Mendelian syndromes","volume":"55","author":"Lim","year":"2003","journal-title":"IUBMB Life"},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13350","article-title":"Structural roles of guide RNAs in the nuclease activity of Cas9 endonuclease","volume":"7","author":"Lim","year":"2016","journal-title":"Nat. Commun."},{"issue":"7113","key":"10.1016\/j.neuint.2026.106149_bib91","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib92","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib93","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3892\/ol.2013.1472","article-title":"PIAS3 promotes homology-directed repair and distal non-homologous end joining","volume":"6","author":"Liu","year":"2013","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib94","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3233\/JPD-181353","article-title":"Modeling Parkinson's disease using patient-specific induced pluripotent stem cells","volume":"8","author":"Li","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/antibiotics8010018","article-title":"Crispr-cas: converting a bacterial defence mechanism into a state-of-the-art genetic manipulation tool","volume":"8","author":"Loureiro","year":"2019","journal-title":"Antibiotics"},{"key":"10.1016\/j.neuint.2026.106149_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.632522","article-title":"In vivo genome editing therapeutic approaches for neurological disorders: where are we in the translational pipeline?","volume":"15","author":"Lubroth","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuint.2026.106149_bib97","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11481-019-09844-3","article-title":"Utilization of the CRISPR-Cas9 gene editing system to dissect neuroinflammatory and neuropharmacological mechanisms in Parkinson's disease","volume":"14","author":"Luo","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib98","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/life11080804","article-title":"The impact of snca variations and its product alpha-synuclein on non-motor features of parkinson's disease","volume":"11","author":"Magistrelli","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.neuint.2026.106149_bib99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/bs.pmbts.2021.01.011","article-title":"CRISPR-Cas systems for genome editing of mammalian cells","volume":"181","author":"Mani","year":"2021","journal-title":"Progr. Mol. Biol. Translat. Sci."},{"issue":"9","key":"10.1016\/j.neuint.2026.106149_bib100","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/1871527313666140806142955","article-title":"The paths to neurodegeneration in genetic Parkinson's disease","volume":"13","author":"Me Abdel-Salam","year":"2014","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"9","key":"10.1016\/j.neuint.2026.106149_bib101","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016428","article-title":"Sources of DNA double-strand breaks and models of recombinational DNA repair","volume":"6","author":"Mehta","year":"2014","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib102","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.semperi.2018.09.003","article-title":"CRISPR\/Cas9 gene-editing: research technologies, clinical applications and ethical considerations","volume":"42","author":"Memi","year":"2018","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.neuint.2026.106149_bib103","article-title":"Delivery platforms for CRISPR\/Cas9 genome editing of glial cells in the central nervous system","volume":"3","author":"Meneghini","year":"2021","journal-title":"Front. Genome Edit."},{"issue":"2","key":"10.1016\/j.neuint.2026.106149_bib104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"24","author":"Moon","year":"2015","journal-title":"Exp. Neurobiol."},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib105","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1166\/jnn.2008.18270","article-title":"Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing","volume":"8","author":"Moreira","year":"2008","journal-title":"J. Nanosci. Nanotechnol."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ncl.2014.09.010","article-title":"Pathogenic mechanisms of neurodegeneration in Parkinson disease","volume":"33","author":"Mullin","year":"2015","journal-title":"Neurol. Clin."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib107","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1038\/s41467-019-11105-z","article-title":"Stimulation of CRISPR-mediated homology-directed repair by an engineered RAD18 variant","volume":"10","author":"Nambiar","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib108","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41434-023-00414-0","article-title":"CRISPR\/sgRNA-directed synergistic activation mediator (SAM) as a therapeutic tool for parkinson' s disease","volume":"31","author":"Narv\u00e1ez-P\u00e9rez","year":"2024","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib109","first-page":"1","article-title":"Advances in the CRISPR\/Cas9 mediated genome editing: a review: CRISPR\/Cas9 mediated genome editing","volume":"56","author":"Nawaz","year":"2019","journal-title":"Proc. Pakistan Acad. Sci.: B. Life Environ. Sci."},{"key":"10.1016\/j.neuint.2026.106149_bib110","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.2147\/DDDT.S424991","article-title":"The coming of age of AI\/ML in drug discovery, development, clinical testing, and manufacturing: the FDA perspectives","author":"Niazi","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s42003-021-02973-7","article-title":"Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson's disease","volume":"5","author":"Novak","year":"2022","journal-title":"Commun. Biol."},{"issue":"20","key":"10.1016\/j.neuint.2026.106149_bib112","first-page":"9555","article-title":"Guide RNA engineering for versatile Cas9 functionality","volume":"44","author":"Nowak","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.neuint.2026.106149_bib113","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib114","first-page":"1211","article-title":"Applications and advancements of CRISPR\/Cas9 technology: an update","volume":"47","author":"Okabe","year":"2021","journal-title":"J. Assoc. Genet. Technol."},{"issue":"12","key":"10.1016\/j.neuint.2026.106149_bib115","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.7150\/thno.83066","article-title":"New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs)","volume":"13","author":"Palanisamy","year":"2023","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib116","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acssynbio.1c00107","article-title":"CRISPR-Cas13 system as a promising and versatile tool for cancer diagnosis, therapy, and research","volume":"10","author":"Palaz","year":"2021","journal-title":"ACS Synth. Biol."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib117","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41380-019-0468-3","article-title":"Modeling Alzheimer's disease with iPSC-derived brain cells","volume":"25","author":"Penney","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuint.2026.106149_bib118","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.parkreldis.2015.08.015","article-title":"Phenotypic spectrum of alpha-synuclein mutations: new insights from patients and cellular models","volume":"22","author":"Petrucci","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib119","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40824-023-00381-y","article-title":"CRISPR\/Cas9 assisted stem cell therapy in Parkinson's disease","volume":"27","author":"Pinjala","year":"2023","journal-title":"Biomater. Res."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40824-023-00381-y","article-title":"CRISPR\/Cas9 assisted stem cell therapy in Parkinson's disease","volume":"27","author":"Pinjala","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.neuint.2026.106149_bib121","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/BF01946641","article-title":"The pharmacology of Parkinson's disease: basic aspects and recent advances","volume":"40","author":"Prada D","year":"1984","journal-title":"Experientia"},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib122","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12032-022-01711-1","article-title":"Artificial intelligence and machine learning in precision and genomic medicine","volume":"39","author":"Quazi","year":"2022","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib123","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/pharmaceutics14061252","article-title":"CRISPR-Cas9-based technology and its relevance to gene editing in Parkinson's disease","volume":"14","author":"Rahman","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuint.2026.106149_bib124","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-019-09849-y","article-title":"Next generation precision medicine: CRISPR-mediated genome editing for the treatment of neurodegenerative disorders","volume":"14","author":"Raikwar","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuint.2026.106149_bib125","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3389\/fnhum.2019.00306","article-title":"G2019S variation in LRRK2: an ideal model for the study of Parkinson's Disease?","volume":"13","author":"Ren","year":"2019","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neuint.2026.106149_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.903812","article-title":"Cas-based systems for RNA editing in gene therapy of monogenic diseases: in vitro and in vivo application and translational potential","volume":"10","author":"Reshetnikov","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuint.2026.106149_bib127","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fnmol.2020.00148","article-title":"Gene-editing technologies paired with viral vectors for translational research into neurodegenerative diseases","volume":"13","author":"Rittiner","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"9","key":"10.1016\/j.neuint.2026.106149_bib128","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/1087057113497256","article-title":"Targeting RNA binding proteins involved in neurodegeneration","volume":"18","author":"Romano","year":"2013","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.neuint.2026.106149_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106675","article-title":"Alpha-synuclein modulates the repair of genomic DNA double-strand breaks in a DNA-PKcs-regulated manner","author":"Rose","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2026.106149_bib130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.addr.2020.07.004","article-title":"Progress and challenges towards CRISPR\/Cas clinical translation","volume":"154","author":"Rosenblum","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.neuint.2026.106149_bib131","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.stem.2020.10.015","article-title":"CRISPR-mediated induction of neuron-enriched mitochondrial proteins boosts direct glia-to-neuron conversion","volume":"28","author":"Russo","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neuint.2026.106149_bib132","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10571-019-00761-w","article-title":"CRISPR system: a high-throughput toolbox for research and treatment of Parkinson's disease","volume":"40","author":"Safari","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45078-3","article-title":"Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson's disease","volume":"13","author":"Sastre","year":"2023","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib134","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/schbul\/sbw035","article-title":"Protein interaction networks link schizophrenia risk loci to synaptic function","volume":"42","author":"Schwarz","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10517-009-0320-x","article-title":"Viral vectors for stable transduction of human mesenchymal stem cells: systems based on adeno-associated viruses and lentiviruses","volume":"146","author":"Shakhbazau","year":"2008","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.neuint.2026.106149_bib136","series-title":"Gene Editing in an International Context: Scientific, Economic and Social Issues Across Sectors; OECD Science, Technology and Industry Working Papers 2018, No. 2018\/04","author":"Shukla-Jones","year":"2018"},{"issue":"7","key":"10.1016\/j.neuint.2026.106149_bib137","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bpj.2017.08.013","article-title":"Mechanism of genome interrogation: how CRISPR RNA-guided Cas9 proteins locate specific targets on DNA","volume":"113","author":"Shvets","year":"2017","journal-title":"Biophys. J."},{"issue":"10","key":"10.1016\/j.neuint.2026.106149_bib138","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2174\/1568026621666210317154502","article-title":"Potential therapeutic relevance of CRISPR\/Cas9 guided epigenetic regulations for neuropsychiatric disorders","volume":"21","author":"Singh","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuint.2026.106149_bib139","series-title":"Genome Engineering via CRISPR-Cas9 System","year":"2020"},{"key":"10.1016\/j.neuint.2026.106149_bib140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.irn.2020.02.009","article-title":"Status and future directions of clinical trials in Parkinson's disease","volume":"154","author":"S\u00f6derbom","year":"2020","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuint.2026.106149_bib141","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.25634.1","article-title":"Recent developments in the treatment of Parkinson's disease","volume":"9","author":"Stoker","year":"2020","journal-title":"F1000Research"},{"issue":"2","key":"10.1016\/j.neuint.2026.106149_bib142","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acsagscitech.1c00270","article-title":"Occurrence and nature of off-target modifications by CRISPR-Cas genome editing in plants","volume":"2","author":"Sturme","year":"2022","journal-title":"ACS Agric. Sci. Technol."},{"key":"10.1016\/j.neuint.2026.106149_bib143","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson's disease","volume":"106","author":"Subramaniam","year":"2013","journal-title":"Prog. Neurobiol."},{"issue":"19","key":"10.1016\/j.neuint.2026.106149_bib144","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1111\/febs.14607","article-title":"Determinants of dopaminergic neuron loss in Parkinson's disease","volume":"285","author":"Surmeier","year":"2018","journal-title":"FEBS J."},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib145","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1289\/ehp.1002839","article-title":"Rotenone, paraquat, and Parkinson's disease","volume":"119","author":"Tanner","year":"2011","journal-title":"Environ. Health Perspect."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib146","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/crispr.2020.0025","article-title":"Translating CRISPR-Cas therapeutics: approaches and challenges","volume":"3","author":"Tay","year":"2020","journal-title":"CRISPR J."},{"issue":"S12","key":"10.1016\/j.neuint.2026.106149_bib147","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1002\/mds.20538","article-title":"Alpha\u2010synuclein dysfunction in Lewy body diseases","volume":"20","author":"Tofaris","year":"2005","journal-title":"Mov. Disord.: Off. J. Movement Dis. Soc."},{"issue":"2","key":"10.1016\/j.neuint.2026.106149_bib148","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.neuint.2026.106149_bib149","first-page":"103","article-title":"Molecular mechanisms defining penetrance of LRRK2-associated Parkinson's disease","volume":"34","author":"Trinh","year":"2022","journal-title":"Med. Genet. : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V"},{"key":"10.1016\/j.neuint.2026.106149_bib150","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.toxrep.2021.03.009","article-title":"Metal elements and pesticides as risk factors for Parkinson's disease-A review","volume":"8","author":"Ullah","year":"2021","journal-title":"Toxicol. Rep."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib151","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1111\/ejn.14689","article-title":"The contribution of Parkin, PINK1 and DJ\u20101 genes to selective neuronal degeneration in Parkinson's disease","volume":"52","author":"Van der Vlag","year":"2020","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2026.106149_bib152","doi-asserted-by":"crossref","DOI":"10.1177\/1179573518787469","article-title":"Unraveling of central nervous system disease mechanisms using CRISPR genome manipulation","volume":"10","author":"Vesikansa","year":"2018","journal-title":"J. Cent. Nerv. Syst. Dis."},{"issue":"46","key":"10.1016\/j.neuint.2026.106149_bib153","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib154","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/21645698.2016.1271856","article-title":"A research program for the socioeconomic impacts of gene editing regulation","volume":"8","author":"Whelan","year":"2017","journal-title":"GM Crops Food"},{"issue":"2","key":"10.1016\/j.neuint.2026.106149_bib155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10730-024-09538-1","article-title":"The ethics of human embryo editing via CRISPR-Cas9 technology: a systematic review of ethical arguments, reasons, and concerns","volume":"37","author":"Wiley","year":"2025","journal-title":"HEC Forum : Interdiscipl. J. Hospitals' Ethical Legal Issues"},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib156","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/biom11081101","article-title":"LRRK2 targeting strategies as potential treatment of Parkinson's disease","volume":"11","author":"Wojewska","year":"2021","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib157","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/tpj.13899","article-title":"The CRISPR\/Cas revolution reaches the RNA world: Cas13, a new Swiss army knife for plant biologists","volume":"94","author":"Wolter","year":"2018","journal-title":"Plant J."},{"issue":"6","key":"10.1016\/j.neuint.2026.106149_bib158","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1016\/j.apsb.2022.03.001","article-title":"Mitochondria targeting drugs for neurodegenerative diseases\u2014Design, mechanism and application","volume":"12","author":"Xu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"31","key":"10.1016\/j.neuint.2026.106149_bib159","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303789120","article-title":"LRRK2 suppresses lysosome degradative activity in macrophages and microglia through MiT-TFE transcription factor inhibition","volume":"120","author":"Yadavalli","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib160","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12951-022-01625-0","article-title":"An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19","volume":"20","author":"Yasamineh","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.neuint.2026.106149_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1737468","article-title":"CRISPR-Cas technologies in neurodegenerative disorders: mechanistic insights, therapeutic potential, and translational challenges","volume":"16","author":"Yashooa","year":"2026","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib163","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.parkreldis.2012.02.018","article-title":"Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease","volume":"18","author":"Yonova-Doing","year":"2012","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib164","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/crispr.2021.0025","article-title":"CRISPR-Cas9 gene editing protects from the A53T-SNCA overexpression-induced pathology of Parkinson's disease in vivo","volume":"5","author":"Yoon","year":"2022","journal-title":"CRISPR J."},{"issue":"4","key":"10.1016\/j.neuint.2026.106149_bib165","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4103\/1008-682X.153851","article-title":"Advantages of using the CRISPR\/Cas9 system of genome editing to investigate male reproductive mechanisms using mouse models","volume":"17","author":"Young","year":"2015","journal-title":"Asian J. Androl."},{"issue":"8","key":"10.1016\/j.neuint.2026.106149_bib166","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00277-023-05510-0","article-title":"Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges","volume":"103","author":"Youssry","year":"2024","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.neuint.2026.106149_bib167","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169931","article-title":"Non-homologous end joining and homology directed DNA repair frequency of double-stranded breaks introduced by genome editing reagents","volume":"12","author":"Zaboikin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neuint.2026.106149_bib168","doi-asserted-by":"crossref","DOI":"10.1017\/S0033583519000052","article-title":"Development of CRISPR-Cas systems for genome editing and beyond","volume":"52","author":"Zhang","year":"2019","journal-title":"Q. Rev. Biophys."},{"issue":"5","key":"10.1016\/j.neuint.2026.106149_bib169","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ar.23723","article-title":"Lentiviral vectors and Adeno\u2010associated virus vectors: useful tools for gene transfer in pain research","volume":"301","author":"Zheng","year":"2018","journal-title":"Anat. Rec."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018626000409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018626000409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:18:10Z","timestamp":1778271490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018626000409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":165,"alternative-id":["S0197018626000409"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2026.106149","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRISPR-Cas systems","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2026.106149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106149"}}